Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
HoUng Kim, Rieke Alten, Fraser Cummings, Silvio Danese, Geert D’Haens, Paul Emery, Subrata Ghosh, Cyrielle Gilletta de Saint Joseph, JongHyuk Lee, James O. Lindsay, Elena Nikiphorou, Ben Parker, Stefan Schreiber, Steven Simoens, Rene Westhovens, Ji Hoon Jeong & Laurent Peyrin-Biroulet. (2021) Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. mAbs 13:1.
Read now
Read now
Yuou Zhang, Xuan Liu, Linghe Yang, Guifang Zhang, Zhaoru Gu, Zhongdan Chen & Jing Sun. (2020) Barriers and Strategies: A Review of Access to Affordable Multi-Drug Resistant Tuberculosis Medication in China. Infection and Drug Resistance 13, pages 3679-3687.
Read now
Read now
Articles from other publishers (11)
Andrea Parziale. (2023) COVID-19 off-label uses of medicines: the role of civil liability and regulation. The Geneva Papers on Risk and Insurance - Issues and Practice 48:3, pages 669-686.
Crossref
Crossref
Velpula Prasannanjaneyulu, Shweta Nene, Harsha Jain, Rimsha Nooreen, Shivam Otavi, Palak Chitlangya & Saurabh Srivastava. (2022) Old drugs, new tricks: Emerging role of drug repurposing in the management of atopic dermatitis. Cytokine & Growth Factor Reviews 65, pages 12-26.
Crossref
Crossref
Hideki Maeda, Ayano Okabe, Kenichi Sakakura, Daniel Bin Ng & Manabu Akazawa. (2021) Relationships between developmental strategies for additional indications and price revisions for anticancer drugs in Japan. BMC Health Services Research 21:1.
Crossref
Crossref
Johnathon Liddicoat, Kathleen Liddell, Mateo Aboy & Jakob Wested. (2021) Has the EU Incentive for Drug Repositioning Been Effective? An Empirical Analysis of the “+1” Regulatory Exclusivity. IIC - International Review of Intellectual Property and Competition Law 52:7, pages 825-851.
Crossref
Crossref
Guoxu Wei, Min Wu, He Zhu, Sheng Han, Jing Chen, Chenchen Zhai & Luwen Shi. (2021) Off-Label Use of Antineoplastic Drugs to Treat Malignancies: Evidence From China Based on a Nationwide Medical Insurance Data Analysis. Frontiers in Pharmacology 12.
Crossref
Crossref
Paola Minghetti, Umberto M. Musazzi, Antonella Casiraghi & Paolo Rocco. (2020) Old active ingredients in new medicinal products: is the regulatory path coherent with patients’ expectations?. Drug Discovery Today 25:8, pages 1337-1347.
Crossref
Crossref
Christine Fetro & Daniel Scherman. (2020) Drug repurposing in rare diseases: Myths and reality. Therapies 75:2, pages 157-160.
Crossref
Crossref
Ciska Verbaanderd, Ilse Rooman, Lydie Meheus & Isabelle Huys. (2020) On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients. Frontiers in Pharmacology 10.
Crossref
Crossref
Konstantinos Ghirtis. 2020. Applied Genomics and Public Health. Applied Genomics and Public Health
345
360
.
Brian Godman, Anna Bucsics, Patricia Vella Bonanno, Wija Oortwijn, Celia C. Rothe, Alessandra Ferrario, Simone Bosselli, Andrew Hill, Antony P. Martin, Steven Simoens, Amanj Kurdi, Mohamed Gad, Jolanta Gulbinovič, Angela Timoney, Tomasz Bochenek, Ahmed Salem, Iris Hoxha, Robert Sauermann, Amos Massele, Augusto Alfonso GuerraJr.Jr., Guenka Petrova, Zornitsa Mitkova, Gnosia Achniotou, Ott Laius, Catherine Sermet, Gisbert Selke, Vasileios Kourafalos, John Yfantopoulos, Einar Magnusson, Roberta Joppi, Margaret Oluka, Hye-Young Kwon, Arianit Jakupi, Francis Kalemeera, Joseph O. Fadare, Oyvind Melien, Maciej Pomorski, Magdalene Wladysiuk, Vanda Marković-Peković, Ileana Mardare, Dmitry Meshkov, Tanja Novakovic, Jurij Fürst, Dominik Tomek, Corrine Zara, Eduardo Diogene, Johanna C. Meyer, Rickard Malmström, Björn Wettermark, Zinhle Matsebula, Stephen Campbell & Alan Haycox. (2018) Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. Frontiers in Public Health 6.
Crossref
Crossref
Jorge Mestre-Ferrandiz, Néboa Zozaya, Bleric Alcalá & Álvaro Hidalgo-Vega. (2018) Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?. PharmacoEconomics 36:12, pages 1407-1420.
Crossref
Crossref